Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...
Overall, Wall Street has a bullish outlook on the stock with a consensus Strong Buy rating. Terns Pharmaceuticals, Inc.
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market ...
Enliven Therapeutics jumped on strong ELVN-001 phase 1b CML data, but a rich valuation may cap upside. Click here to read an ...
The final, formatted version of the article will be published soon. Abstract: Background: Early switching of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), particularly within ...
The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...
Ltd on Monday said it has received tentative approval from the US health regulator for its Bosutinib tablets used in the ...
The pharma business also announced that it has already secured final USFDA approvals for Bosutinib Tablets in the 100 mg and ...
Alembic Pharmaceuticals Ltd has obtained tentative approval from the USFDA for its Bosutinib tablets, used to treat specific ...
Alembic Pharmaceuticals announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its supplemental Abbreviated New Drug Application (sANDA) for Bosutinib ...
Alembic Pharmaceuticals receives USFDA tentative approval for generic Bosutinib tablets, a cancer treatment drug. ANDA ...
Bosutinib is a kinase inhibitor used in the treatment of adult patients with Philadelphia chromosome-positive chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback